Neurogene Quarterly Cash Flow Statement
NASDAQ: NGNEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
26.40-0.10 (-0.38%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neurogene free cash flow
In the quarter ended Jun 30, 2026, Neurogene generated -$23.8 million of operating cash flow and spent $354,000 on capital expenditures. That left free cash flow of -$24.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Neurogene cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -34.49M | -30.93M | -24.73M | -20.95M | -22.02M | -22.65M | -19.51M | -20.22M | -18.49M | -16.92M | 2.38M | -14.58M |
| Net Income growth (YoY) | — | — | — | — | — | — | -918.88% | — | — | — | — | — |
| Depreciation & Amortization | 813.00K | 847.00K | 776.00K | 800.00K | 800.00K | 749.00K | 785.00K | 800.00K | 800.00K | 814.00K | 817.00K | 800.00K |
| Stock-Based Compensation | 7.86M | 3.63M | 3.36M | 3.37M | 3.41M | 4.05M | 2.49M | 2.47M | 2.31M | 1.04M | 355.00K | 386.00K |
| Change in Working Capital | -1.15M | 2.38M | 439.00K | -468.00K | -1.18M | 1.77M | -602.00K | -24.00K | 182.00K | 156.00K | -1.61M | 657.00K |
| Operating Cash Flow | -23.76M | -26.12M | -17.43M | -19.51M | -19.46M | -20.77M | -17.50M | -15.56M | -15.89M | -21.65M | -16.97M | -11.57M |
| Capital Expenditures | -354.00K | -281.00K | -128.00K | -127.00K | -148.00K | -780.00K | -116.00K | -167.00K | -460.00K | -65.00K | -128.00K | -82.00K |
| Investing Cash Flow | 6.10M | 46.24M | 29.61M | 21.99M | 7.45M | -45.05M | -102.62M | -28.97M | -23.61M | 29.93M | 25.83M | -82.00K |
| Financing Cash Flow | 5.98M | 195.00K | 20.66M | 9.71M | 54.00K | 4.00K | 190.06M | 131.00K | 399.00K | -6.52M | 94.30M | -1.84M |
| Net Change in Cash | -11.68M | 20.32M | 32.84M | 12.19M | -11.96M | -65.81M | 69.95M | -44.40M | -39.11M | 1.76M | 103.16M | -13.49M |
| Free Cash Flow | -24.11M | -26.40M | -17.56M | -19.64M | -19.61M | -21.55M | -17.61M | -15.73M | -16.35M | -21.71M | -17.10M | -11.65M |
This table shows 12 quarterly periods of Neurogene's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NGNE's reporting calendar. What is a cash flow statement?